Palace guard in Stockholm
Stockholm, Sweden – The annual meeting of the European Hematology Association (EHA) is in full swing with updated data from two blue companies, Blueprint Medicines and bluebird bio of interest to BSB readers.
There is often beauty and simplicity to be found in nature that also applies to oncology R&D.
One of those aspects can be found in the concept of targeting particular aberrations or molecular rearrangements that driven oncogenic activity. Once you connect the dots to arrive at these key targets, you can develop therapeutics that inhibit the activity, resulting in cessation or reduction in proliferation.
In our latest post, we focus on an update on Blueprint Medicine and take a look at their various programs in early clinical development, as they have quite a lot going on with multiple targeted compounds in different areas, including hematology.
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the recent Triple (EORTC-NCI-AACR) and ASH meetings, Blueprint Medicines (Cambridge, MA) presented data on some of their targeted compounds in early clinical development including data in KIT, PDGFα and FGFR4 driven cancers.
While many observers attention is currently distracted on cancer immunotherapies, let’s not take our eye off the ball and forget that when we do find driver oncogenes in rare tumours, the activity of TKIs can still be superior in these situations and offer exquisite sensitivity, leading to exceptional responses.
Here, we take stock with a look what Blueprint are doing, where they’re going and also offer some perspectives from senior company executives, whom we interviewed last month.
Which reminds me, someone recently asked why we do so many interviews, “You do a prodigious amount of interviews on BSB, why is that?”
The answer is very simple – to learn faster and share that knowledge with other like minded souls. Charlie Ambler, author of Daily Zen, sums it up well in an essay about Talk Less:
“In Zen tradition, I’d like the kill the Buddha that is Lao Tzu and revise his ancient saying. It’s not that those who talk don’t know and those who know don’t talk— it’s that talking often inhibits us from knowing.”
Thus, the corollary here is that if you undertake interviews with scientists and researchers regularly then you have the pleasure of talking less – the person in the hotseat naturally talks more – and you learn faster.
What’s not to like? We all learn different things depending on our perspective and knowledge base. Sometimes, I even find re-reading old interviews a year or so later while preparing for a new one a related topic teaches me something new I didn’t see or realise before, simply because my own understanding has improved. Hopefully that is also true for subscribers!
To learn more insights about this promising small biotech, including an interview with company executives, subscribers can log-in